NorthWest Biotherapeutics Inc (NWBO)

[Galzus Research]

So the answer is no. If you don’t want to understand, that’s fine. But POLO was a positive trial, shifted treatment guidelines, got approval, and has been a highly, highly criticized study.

It was published in the NEJM, with a who’s who of pancreas cancer researchers. That doesn’t stop a trial from being criticized by others, most notably Vinay Prasad.

And no, it’s not DCVax. DCVax isn’t in treatment guidelines, nor does it have approval, nor does it improve PFS. POLO was a more convincingly positive trial, and it was still subject to criticism

TL;DR (because people aren’t bothering to), the authorship of a journal article does not render it immune to criticism. And any of those authors in the JAMA paper would acknowledge that it did not go according to plan, and therefore has limitations, which are delineated in the article itself.